Aprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen – Role in Effectiveness of Prevention of Nausea and Vomiting
Olanzapine exhibited greater efficacy in preventing nausea, particularly in the acute phase, compared to aprepitant. However, its higher side effect profile suggests that careful patient selection is necessary. Both agents remain effective options for CINV management, with olanzapine offering an advantage in nausea prevention.
Authors
- Dibyajyoti Saikia (ORCID: https://orcid.org/0000-0002-1977-5901)
- Indrani Sarma (ORCID: https://orcid.org/0009-0007-6211-5398)
- Neelakshi Mahanta (ORCID: https://orcid.org/0009-0009-5316-0722)
- Joonmoni Lahon (ORCID: https://orcid.org/0000-0002-9937-1789)
- Sukainnya Buragohain (ORCID: https://orcid.org/0000-0003-3457-374X)
- Indrani Bhagawati
Institutions
- Gauhati Medical College and Hospital (IN)
- Bhubaneswar Borooah Cancer Institute (IN)
- Cancer Institute (WIA) (IN)
- National Institute of Pharmaceutical Education and Research (IN)
- All India Institute of Medical Sciences Guwahati (IN)
- Assam Medical College (IN)
Publication Details
- Journal
- Acta medica Lituanica
- Published
- 2025-06-09
- DOI
- https://doi.org/10.15388/amed.2025.32.1.22
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 0.00